کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3328154 | 1212301 | 2014 | 19 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Rekomendacje diagnostyczne i terapeutyczne dla przewlekÅej biaÅaczki limfocytowej w 2014 r. - raport Grupy Roboczej PTHiT oraz PALG - CLL
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
analogi purynrytuksymabPurine nucleoside analogs - آنالوگهای نوکلئوزید پورینprzeciwciała monoklonalne - آنتیبادیهای مونوکلونالnowe leki - داروهای جدیدRituximab - ریتوکسیمابNew agents - عوامل جدیدprzewlekła białaczka limfocytowa - لوسمی لنفوسیتی مزمنChronic lymphocytic leukemia - لوسمی مزمن لنفوئیدیMonoclonal antibodies - پادتنهای تَکتیرهChlorambucil - کلمبوچییل
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Rekomendacje diagnostyczne i terapeutyczne dla przewlekÅej biaÅaczki limfocytowej w 2014 r. - raport Grupy Roboczej PTHiT oraz PALG - CLL Rekomendacje diagnostyczne i terapeutyczne dla przewlekÅej biaÅaczki limfocytowej w 2014 r. - raport Grupy Roboczej PTHiT oraz PALG - CLL](/preview/png/3328154.png)
چکیده انگلیسی
Chronic lymphocytic leukemia (CLL) is predominantly a disease of the elderly, with a median age of 70 years at diagnosis. Appropriate treatment approach requires physical examination, evaluation of performance status, co-morbidities and severity of comorbid conditions, biological age, peripheral, blood count with morphologic examination. In addition, in some patients bone marrow evaluation, serum biochemistry including serum lactate dehydrogenasis and β2-microglobulin, Coombs' test, imaging of adenomegalies, assessed either by CT scan or by the combination of chest X-ray and abdomen ultrasound should be incorporated into decision-making process with regard to intensity of treatment. In patients requiring therapy, particularly a second-line treatment, del 17p and/or p53 mutations should be also checked. Elderly and/or comorbid patients with CLL may not tolerate more aggressive approach due to high risk of unacceptable toxicity of purine nucleoside analogs, especially in combination with cyclophosphamide and rituximab. Therefore in these patients population, chlorambucil +/- rituximab is still accepted as the first-line treatment and chlorambucil remains the backbone of treatment against which the new protocols should be tested. The results of ongoing trials investigating the role of new immunochemotherapies and the other novel agents will probably modify the treatment of CLL in the following years. In this article we present recommendations for diagnosis, prognosis and therapy of CLL elaborated by by PTH i T and PALG-CLL group.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Acta Haematologica Polonica - Volume 45, Issue 3, JulyâSeptember 2014, Pages 221-239
Journal: Acta Haematologica Polonica - Volume 45, Issue 3, JulyâSeptember 2014, Pages 221-239
نویسندگان
Tadeusz Robak, Iwona Hus, Jerzy BÅoÅski, Krzysztof Giannopoulos, Krzysztof Jamroziak, Jacek RoliÅski, Piotr Smolewski, Dariusz WoÅowiec,